AAM Launches Further Broadside At Proposed Blocking Act

Proposed Act ‘Well-Intended But Misguided,’ AAM Claims

A proposed US House bill that would prevent the first generic filer to challenge patents listed against the reference brand from ‘parking’ their 180-day market exclusivity has once again come under fire from the AAM.

Delays
Weakening the 180-day exclusivity incentive will delay patient access, the AAM insists • Source: Shutterstock

More from Policy & Regulation

More from Generics Bulletin